Bromocriptine in systemic lupus erythematosus: A double-blind, randomized, placebo-controlled study

Lupus

Volumn 7, Issue 6, 1998, Pages 414-419

  Alvarez Nemegyei, J ^a   Cobarmbias Cobos, A ^a   Escalante Triay, F ^a   Sosa Munoz J ^a   Miranda, J M ^b   Jara, L J ^b,c  

^a Rheumatology Department   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

Bromocriptine; Erythematosus; Prolactin; Systemic lupus

Indexed keywords

AZATHIOPRINE; BROMOCRIPTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; PROLACTIN;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME;

ADULT; BROMOCRIPTINE; DOUBLE-BLIND METHOD; FEMALE; HORMONE ANTAGONISTS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PREGNANCY; PROLACTIN; TREATMENT OUTCOME;

EID: 0031661701     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120398678920334     Document Type: Conference Paper

References (32)

1. Berczi I. Prolactin, pregnancy and autoimmune diseases. J Rheumatol 1993; 20: 1095-1100.
2. Walker SE, Allen SH, Hoffman RW, McMurray RW. Prolactin: a stimulator of disease activity in systemic lupus erythematosus. Lupus 1995; 4: 3-9.
3. Besedovsky HO, Del Rey A. Immuno-neuro-endocrine interactions: facts and hypothesis. Endocr Rev 1996; 17: 64-102.
4. Jara LJ et al. Hyperprolactinemia in systemic lupus erythematosus: association with disease activity. Am J Med Sci 1992; 303: 222-226.
5. Jara-Quezada LJ, Graef A, Lavalle C. Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus. J Rheumatol 1991; 18: 349-353.
6. Lavalle C et al. Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus. J Rheumatol 1987; 14: 268-272.
7. McMurray R et al. Prolactin influences autoimmune disease activity in the female B/W mouse. J Immunol 1991, 147: 3787-3790.
8. Gutiérrez MA et al. Prolactin and systemic lupus erythematosus: prolactin secretion by lymphocytes and proliferative (autocrine) activity. Lupus 1995; 4: 348-352.
9. Larrea F et al. A bioactive 60-kilodalton prolactin species is preferentially secreted in cultures of mitogen-stimulated and non-stimulated peripheral blood mononuclear cells from subjects with systemic lupus erythematosus. J Clin Endocrinol Metab 1997; 82: 3664-3669.
10. Gutiérrez MA et al. Prolactin-induced immunoglobulin and autoantibody production by peripheral blood mononuclear cells from systemic lupus erythematosus and normal individuals. Int Arch Allergy Immunol 1996; 109: 229-235.
11. Brennan P et al. Allelic markers close to prolactin are associated with HLA-DRB1 susceptibility alleles among women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1383-1386.
12. Buskita D, Shoenfeld Y. Prolactin, bromocriptme, and autoimmune diseases. Isr J Med 1996; 32: 23-27.
13. Bravo G, Zazueta B, Lavalle C An acute remission of Reiter's syndrome in male patients treated with bromocriptine. J Rheumatol 1992; 19: 747-750.
14. Weber G, Frey H. Treatment of psoriatic arthritis with bromocriptine. J Am Acad Dermatol 1987; 16: 388-389.
15. Hender LP, Bynke G. Endogenous iridocyclitis relieved during treatment with bromocriptine. Am J Opthalmol 1985; 109: 618-619
16. McMurray RW, Weindensaul D, Allen SH, Walker SE. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus crythematosus. J Rheumatol 1995; 22: 2084-2091.
17. Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
18. Bombardier C et al. Committee on prognosis studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
19. Petri M et al. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991; 34: 937-944
20. Vance ML, Thorner MO. Prolactin: Hyperprolactinemic syndromes and management. In: DeGroot LJ (ed). Endocrinology. W.B. Saunders Co.: Philadelphia, 1989; 408.
21. Nagy E et al. Immunomodulation by bromocriptine. Immunopharmacology 1983; 6: 231-243.
22. Bernton EW, Meltzer MS, Holaday JE. Suppression of macrophage activation and T lymphocyte function in hypoprolactinemic mice. Science 1988; 239: 401-404.
23. Neidhart M Bromocriptine microcapsules inhibit ornithine decarboxylase activity induced by Freund's complete adjuvant in lymphoid tissues of male rats . Endocrinology 1989, 125: 2846-2852.
24. Riskind PN, Massacesi L, Doolittle RH, Hauser SL The role of prolactin in autoimmune demyelination: suppression of experimental allergic encephalomyelitis by bromocriptine. Ann Neurol 1991; 29: 542-547.
25. Blank M, Palestine A, Nusenblant R, Shoenfeld Y. Down-regulation of autoantibody levels with cyclosporine and bromocriptine treatment in uveitis Clin Immunol Immunophatol 1990; 54: 87-97.
26. Morikawa K, Oseko F, Morikawa S. Immunosuppressive property of bromocriptine on human B lymphocyte function in vitro. Clin Exp Immunol 1993; 93: 200-205.
27. Morikawa K, Oseko F, Morikawa S. Immunosuppressive activity of bromocriptine on human T lymphocyte function in vitro. Clin Exp Immunol 1994; 95- 514-518.
28. Blank M et al. Bromocriptine immunomodulation of experimental SLE and primary anti-phospholipid syndrome via induction of non-specific T suppressor cells. Cell Immunol 1995; 162: 114-122.
29. Neidhart M. Elevated serum prolactin or elevated prolactin/cortisol ratio are associated with autoimmune processes in SLE and other CTD J Rheumatol 1996; 23: 476-481.
30. Miranda JM et al. Prolactin (PRL) and interleukin-6 (IL-6) in severe lupus glomerulonephritis. Arthritis Rheum 1997; 40: 3106 (abstract 455).
31. Jara LJ et al. Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus. Clin Rheumatol (in press).
32. Rovensky J et al. Relationship between endocrine, immune and clinical variables in patients with systemic lupus erythematosus. J Rheumatol 1997; 24: 2330-2334.